Aviso: Este site agrega dados públicos oficiais da FDA, ClinicalTrials.gov, PubMed e SEC EDGAR apenas para referência geral. Não constitui aconselhamento médico, diagnóstico, recomendação de tratamento ou aconselhamento de investimento.

PubMed

Remote Cardiac Safety Monitoring through the Lens of the FDA Biomarker Qualification Evidentiary Criteria Framework: A Case Study Analysis.

PMID: 34056520 ·

E, l, e, n, a, , S, , I, z, m, a, i, l, o, v, a, ;, , W, i, l, l, i, a, m, , A, , W, o, o, d, ;, , Q, i, , L, i, u, ;, , V, a, d, i, m, , Z, i, p, u, n, n, i, k, o, v, ;, , D, a, n, i, e, l, , B, l, o, o, m, f, i, e, l, d, ;, , J, a, s, o, n, , H, o, m, s, y, ;, , S, t, e, v, e, n, , C, , H, o, f, f, m, a, n, n, ;, , J, o, h, n, , A, , W, a, g, n, e, r, ;, , J, o, s, e, p, h, , P, , M, e, n, e, t, s, k, i

RevistaDigital biomarkers
Ano
PMID34056520

Resumo

Clinical safety findings remain one of the reasons for attrition of drug candidates during clinical development. Cardiovascular liabilities are not consistently detected in early-stage clinical trials and often become apparent when drugs are administered chronically for extended periods of time. Vital sign data collection outside of the clinic offers an opportunity for deeper physiological characterization of drug candidates and earlier safety signal detection. A working group representing exper

Fonte oficial

Ver no PubMed →

Dados provenientes do PubMed / NCBI. Para consultar o texto integral e as informações mais recentes, recorra sempre ao registo oficial.

↑